AMP UK Introduces OraFusion

Aesthetic Medical Partnership has launched the BeVigilant™ OraFusion™ System in the UK and Ireland - a salivary biomarker testing platform designed for use in primary care settings, including dental and aesthetic practices,
Aesthetic Medical Partnership has introduced the BeVigilant OraFusion System, a new chairside screening tool that provides an objective indication of whether patients may require further investigation, supporting clinical decision-making directly within the appointment. The platform uses a saliva-based lateral flow immunoassay and integrated digital reader to analyse biomarker levels alongside patient clinical risk factors.
With results available in 15 minutes or less, OraFusion delivers a clear Monitor or Investigate Further outcome to inform potential referral pathways.
The need for earlier assessment remains significant: 29% of dental patients present with an oral abnormality during routine visits and 72% of oral cancer cases are diagnosed late - at Stage III or IV. Incorporating objective testing into regular examinations may help strengthen early identification strategies.
To find out more about integrating OraFusion into a clinical practice - and the difference it can make to early assessment – contact AMP UK for a no-obligation call.